CDIO vs. JSPR, OSTX, COYA, HLVX, MNOV, XFOR, IMUX, EDIT, ABOS, and ORMP
Should you be buying Cardio Diagnostics stock or one of its competitors? The main competitors of Cardio Diagnostics include Jasper Therapeutics (JSPR), OS Therapies (OSTX), Coya Therapeutics (COYA), HilleVax (HLVX), MediciNova (MNOV), X4 Pharmaceuticals (XFOR), Immunic (IMUX), Editas Medicine (EDIT), Acumen Pharmaceuticals (ABOS), and Oramed Pharmaceuticals (ORMP). These companies are all part of the "pharmaceutical products" industry.
Cardio Diagnostics vs.
Jasper Therapeutics (NASDAQ:JSPR) and Cardio Diagnostics (NASDAQ:CDIO) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability, community ranking and risk.
Jasper Therapeutics presently has a consensus price target of $67.75, suggesting a potential upside of 1,129.58%. Cardio Diagnostics has a consensus price target of $2.00, suggesting a potential upside of 277.64%. Given Jasper Therapeutics' higher possible upside, equities research analysts plainly believe Jasper Therapeutics is more favorable than Cardio Diagnostics.
Jasper Therapeutics received 40 more outperform votes than Cardio Diagnostics when rated by MarketBeat users. Likewise, 89.80% of users gave Jasper Therapeutics an outperform vote while only 80.00% of users gave Cardio Diagnostics an outperform vote.
79.9% of Jasper Therapeutics shares are held by institutional investors. Comparatively, 8.1% of Cardio Diagnostics shares are held by institutional investors. 2.7% of Jasper Therapeutics shares are held by insiders. Comparatively, 22.3% of Cardio Diagnostics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Jasper Therapeutics has a net margin of 0.00% compared to Cardio Diagnostics' net margin of -22,777.20%. Jasper Therapeutics' return on equity of -67.64% beat Cardio Diagnostics' return on equity.
Jasper Therapeutics has a beta of 2.18, indicating that its stock price is 118% more volatile than the S&P 500. Comparatively, Cardio Diagnostics has a beta of 3.76, indicating that its stock price is 276% more volatile than the S&P 500.
In the previous week, Jasper Therapeutics had 4 more articles in the media than Cardio Diagnostics. MarketBeat recorded 4 mentions for Jasper Therapeutics and 0 mentions for Cardio Diagnostics. Cardio Diagnostics' average media sentiment score of 1.00 beat Jasper Therapeutics' score of 0.61 indicating that Cardio Diagnostics is being referred to more favorably in the news media.
Cardio Diagnostics has higher revenue and earnings than Jasper Therapeutics.
Summary
Jasper Therapeutics beats Cardio Diagnostics on 9 of the 14 factors compared between the two stocks.
Get Cardio Diagnostics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CDIO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cardio Diagnostics Competitors List
Related Companies and Tools
This page (NASDAQ:CDIO) was last updated on 1/21/2025 by MarketBeat.com Staff
